Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Last Updated: June 25, 2022

Oncopeptides Ab Company Profile

✉ Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for ONCOPEPTIDES AB, and what generic alternatives to ONCOPEPTIDES AB drugs are available?

ONCOPEPTIDES AB has one approved drug.

There are five US patents protecting ONCOPEPTIDES AB drugs.

There are seventy-six patent family members on ONCOPEPTIDES AB drugs in twenty-seven countries.

Summary for Oncopeptides Ab

International Patents:	76
US Patents:	5
Tradenames:	1
Ingredients:	1
NDAs:	1

Drugs and US Patents for Oncopeptides Ab

+ Get email alerts for changes to this table

Subscribe to access the full database, or Try it Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Oncopeptides Ab	PEPAXTO	melphalan flufenamide hydrochloride	POWDER;INTRAVENOUS	214383-001	Feb 26, 2021		DISCN	Yes	No		See Plans and Pricing				See Plans and Pricing
Oncopeptides Ab	PEPAXTO	melphalan flufenamide hydrochloride	POWDER;INTRAVENOUS	214383-001	Feb 26, 2021		DISCN	Yes	No	10,543,274	See Plans and Pricing				See Plans and Pricing
Oncopeptides Ab	PEPAXTO	melphalan flufenamide hydrochloride	POWDER;INTRAVENOUS	214383-001	Feb 26, 2021		DISCN	Yes	No	10,285,946	See Plans and Pricing	Y			See Plans and Pricing
Oncopeptides Ab	PEPAXTO	melphalan flufenamide hydrochloride	POWDER;INTRAVENOUS	214383-001	Feb 26, 2021		DISCN	Yes	No	10,322,182	See Plans and Pricing	Y			See Plans and Pricing
Oncopeptides Ab	PEPAXTO	melphalan flufenamide hydrochloride	POWDER;INTRAVENOUS	214383-001	Feb 26, 2021		DISCN	Yes	No	10,869,928	See Plans and Pricing	Y			See Plans and Pricing
Oncopeptides Ab	PEPAXTO	melphalan flufenamide hydrochloride	POWDER;INTRAVENOUS	214383-001	Feb 26, 2021		DISCN	Yes	No	6,992,207	See Plans and Pricing	Y	Y		See Plans and Pricing
Oncopeptides Ab	PEPAXTO	melphalan flufenamide hydrochloride	POWDER;INTRAVENOUS	214383-001	Feb 26, 2021		DISCN	Yes	No		See Plans and Pricing				See Plans and Pricing
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for Oncopeptides Ab Drugs

Subscribe to access the full database, or Try it Free
Country	Patent Number	Estimated Expiration
Serbia	60719	See Plans and Pricing
Japan	4798930	See Plans and Pricing
Hungary	E051690	See Plans and Pricing
China	103547279	See Plans and Pricing
Spain	2768268	See Plans and Pricing
Israel	280812	See Plans and Pricing
Australia	2012247545	See Plans and Pricing
>Country	>Patent Number	>Estimated Expiration

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson

Moodys

AstraZeneca

Medtronic

Johnson and Johnson

Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.